From the USA: Overtreatment of Prostate Cancer Increasing in Men With Short Life Expectancy
In the active surveillance era, overtreatment of men with limited life expectancy (LE) decreased for those with low-risk prostate cancer, but increased for those with intermediate-risk and high-risk disease from 2000 to 2019, according to a study published online Nov. 11 in JAMA Internal Medicine.
Timothy J. Daskivich, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues examined if rates of overtreatment of men with limited LE have persisted in the active surveillance era and whether overtreatment varies by tumor risk or treatment type. The analysis included 243,928 men with clinically localized prostate cancer diagnosed in the Veterans Affairs (VA) health system from 2000 through 2019.
Source: Advances and More licensed by HealthDay
